×

Ii-key/antigenic epitope hybrid peptide vaccines

  • US 20060002947A1
  • Filed: 01/11/2005
  • Published: 01/05/2006
  • Est. Priority Date: 09/14/1999
  • Status: Active Grant
First Claim
Patent Images

1. An antigen presentation enhancing hybrid polypeptide comprising the following elements:

  • a) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR (SEQ ID NO;

    1 and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity;

    b) a chemical structure covalently linking the N-terminal element of step a) to the MHC Class II-presented epitope of element c), the chemical structure being a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of;

    i) immunologically neutral chemical structures;

    ii) a MHC Class I epitope or a portion thereof; and

    /or iii) an antibody-recognized determinant or a portion thereof; and

    c) a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II molecule.

View all claims
  • 9 Assignments
Timeline View
Assignment View
    ×
    ×